Disorders Causing Seizures Codexery

Phenylketonuria

Inherited metabolic disorder treatable with a strict low-phenylalanine diet.

Phenylketonuria

Phenylketonuria (PKU) is a genetic metabolic disorder where the body cannot properly break down the amino acid phenylalanine. Without treatment, this condition can cause intellectual disability, seizures, behavioral issues, and mental disorders, along with a musty body odor and unusually light skin. It is inherited when a child receives two mutated copies of the PAH gene—one from each parent. This gene normally provides instructions for making the enzyme phenylalanine hydroxylase, which processes excess phenylalanine. When the enzyme is missing or doesn't work well, phenylalanine builds up to harmful levels. People with just one mutated gene copy are carriers and usually have no symptoms. There are two main types: classic PKU, where almost no enzyme works, and variant PKU, where some function remains.

Newborns with PKU appear normal at birth because the mother's body handles phenylalanine during pregnancy. For this reason, the disease is not detectable by physical exam, so many countries screen newborns using a blood sample from a heel prick, typically taken two to seven days after birth. This test can show high phenylalanine levels after a day or two of normal feeding. If a child isn't diagnosed early and doesn't start a low-phenylalanine diet, blood levels rise over time. Toxic amounts of phenylalanine, along with low levels of tyrosine, can permanently harm infant development. Untreated children may have seizures, very fair hair and skin, and a musty or mousy odor in sweat and urine from phenylacetate. They often miss early developmental milestones, develop a small head, and show worsening brain function. Later in life, hyperactivity, abnormal brain waves, seizures, and severe learning disabilities are common. A musty smell and a tendency toward eczema can persist without treatment. Brain damage from the first months of life is not reversible. However, children detected at birth and treated are much less likely to have these neurological problems, though they still face higher risks for conditions like asthma, eczema, anemia, weight gain, kidney issues, osteoporosis, stomach problems, kidney stones, and high blood pressure. Mood disorders occur 230% more often than in the general population, dizziness 180% more, and chronic heart disease, asthma, diabetes, and stomach infections 170% more.

Quick Facts

Field
Medical genetics, pediatrics, dietetics
Symptoms
Without treatment: intellectual disability, seizures, hyperactivity, psychiatric problems, musty odor
Onset
At birth
Duration
Lifelong
Types
Classic, variant
Causes
Genetic (autosomal recessive)
Diagnosis
Newborn screening programs in many countries
Treatment
Diet low in foods that contain phenylalanine; special supplements
Medication
Sapropterin dihydrochloride, pegvaliase
Prognosis
Normal health with treatment
Frequency
~1 in 12,000 newborns

Facts from the source article.

Lore & Background

Phenylketonuria (PKU) was discovered in 1934 by Ivar Asbjørn Følling, with the importance of diet determined in 1935. It is an autosomal recessive disorder, meaning both copies of the PAH gene must be mutated for the condition to develop. Those with one copy of a mutated gene typically do not have symptoms. The two main types are classic PKU and variant PKU, depending on whether any enzyme function remains.

Treatment is with a diet low in foods that contain phenylalanine and includes special supplements. Babies should use a special formula with a small amount of breast milk. The diet should begin as soon as possible after birth and continue for life. People who are diagnosed early and maintain a strict diet can have normal health and a normal lifespan. Effectiveness is monitored through periodic blood tests. The medication sapropterin dihydrochloride may be useful in some.

Many countries have newborn screening programs for the disease. A baby born to a mother who has poorly treated PKU may have heart problems, a small head, and low birth weight. As of 2023, genetic therapies that aim to directly restore liver PAH activity are a promising and active research field.

Reader's Guide

Phenylketonuria is significant as a model for treatable genetic disorders through early detection and dietary management. Its discovery in 1934 by Ivar Asbjørn Følling and the subsequent determination of diet's importance in 1935 laid the groundwork for newborn screening programs worldwide. The condition affects about one in 12,000 babies, with males and females affected equally. Untreated PKU leads to severe intellectual disability, seizures, and other neurological problems, but early diagnosis and a lifelong low-phenylalanine diet can allow normal health and lifespan. The disorder also highlights the role of carrier status: carriers do not exhibit symptoms but may have a selective advantage against the fungal toxin ochratoxin A. Ongoing research into genetic therapies aims to restore liver PAH activity, offering potential future treatments beyond dietary restriction.

Did You Know?

More in Disorders causing seizures 1-24

Spotted an error? Know more?

Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced

Comments

Loading…
Open in the interactive codex →